Profound Medical Corp.
PROF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PROF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PROF
Profound Medical Corp. (PROF) is a commercial-stage medical device company developing and marketing TULSA-PRO and Sonalleve, therapeutic platforms for minimally invasive ablation in urology and gynecology, with a hybrid recurring revenue model in the U.S.
Key risk: Ongoing net losses
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Profound Medical Corp..
Profound Medical Corp. (PROF) is a commercial-stage medical device company developing and marketing TULSA-PRO and Sonalleve, therapeutic platforms for minimally invasive ablation in urology and gynecology, with a hybrid recurring revenue model in the U.S.
- Cash and equivalents of $38.3M as of 2026-06-30 [sec].
- Total revenue of $2.5M and net loss of -$9.5M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $66.4M and total debt of $9.0M as of 2026-06-30 [sec].
- TULSA-PRO is cleared by the FDA; Sonalleve is CE marked for uterine fibroids and bone metastases, and approved in China for uterine fibroids [sec · filed 2026-05-12].
- Expects existing cash and product sales to fund operations for at least 12 months from the date of the latest unaudited financial statements [sec_mda · as of 2026-08-06].
What works
- TULSA-PRO and Sonalleve are both FDA-cleared or approved, providing regulatory clarity for U.S. commercialization [sec · filed 2026-05-12].
- Hybrid recurring revenue business model in the U.S. may generate predictable, recurring income from procedure-based sales [sec · filed 2026-05-12].
- Cash runway of at least 12 months from mid-2026 reduces near-term financing risk [sec_mda · as of 2026-08-06].
What to weigh
- The company has historically experienced recurring losses and an accumulated deficit of $279.6M through September 30, 2025 [sec_mda · as of 2025-11-13].
- Net loss of -$9.5M for the six months ended June 30, 2026 indicates ongoing cash burn [sec].
- Dependence on future equity or debt financing may cause dilution or increased debt service obligations [sec_mda · as of 2026-05-07].
- Cash decreased from $59.7M (Dec 2025) to $38.3M (Jun 2026), reflecting significant cash consumption [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash and equivalents as of June 30, 2026
“As of June 30, 2026, we had cash of $38,271”
SEC MD&A · August 6, 2026
Accumulated deficit through September 30, 2025
“accumulated deficit of $279,566 through September 30, 2025”
SEC MD&A · November 13, 2025
FDA clearance of TULSA-PRO and Sonalleve approvals
“cleared by the U.S. Food and Drug Administration ("FDA"). We are also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.”
SEC filings · May 12, 2026
Cash runway of at least 12 months
“we expect that our existing cash and sales of our products and services will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Ongoing net losses — Net loss of -$9.5M for six months ended Jun 2026; accumulated deficit of $279.6M [sec] [sec_mda]
- Cash burn rate — Cash dropped from $59.7M (Dec 2025) to $38.3M (Jun 2026), a decline of ~36% in six months [sec_mda]
- Dependence on future financing — May need additional capital; equity financing would dilute shareholders, debt would increase obligations [sec_mda · as of 2026-05-07]
- Commercial adoption uncertainty — Cash requirements depend on market acceptance of TULSA-PRO and Sonalleve; slow adoption could strain liquidity [sec_mda · as of 2026-08-06]
What to watch
- Quarterly revenue growth from TULSA-PRO and Sonalleve procedures, as a key indicator of commercial traction [sec_mda · as of 2026-08-06].
- Cash burn rate and any updates to cash runway guidance in future SEC filings [sec_mda · as of 2026-08-06].
- Regulatory developments for Sonalleve in additional indications (e.g., abdominal cancers) [sec · filed 2026-05-12].
- Potential new strategic partnerships or financing events that could affect dilution or debt levels [sec_mda · as of 2026-05-07].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Profound Medical Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Profound Medical Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
11.8 months
D/E 0.25 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
54
Total value held
$80.7M
| Holder | Shares | Value |
|---|---|---|
| fil ltd | 2,340,000 | $15.2M |
| gagnon securities llc | 1,944,324 | $12.6M |
| royce & associates lp | 1,116,348 | $7.1M |
| letko, brosseau & associates inc | 953,175 | $6.1M |
| mmcap international inc. spc | 745,152 | $4.8M |
| first eagle investment management, llc | 645,414 | $4.2M |
| ardsley advisory partners lp | 575,000 | $3.7M |
| royal bank of canada | 493,060 | $3.2M |
| lagoda investment management, l.p. | 441,015 | $2.9M |
| velan capital investment management lp | 285,710 | $1.9M |
Showing top 10 of 54 institutional holders of Profound Medical Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 11, 2026- % of float
- 6.5%
- Days to cover
- 9.9
- Shares short
- 2,091,784
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PROF short interestGovernance
Frequently asked questions
What is the AI investment thesis for Profound Medical Corp.?
Profound Medical Corp. (PROF) is a commercial-stage medical device company developing and marketing TULSA-PRO and Sonalleve, therapeutic platforms for minimally invasive ablation in urology and gynecology, with a hybrid recurring revenue model in the U.S.
What is Profound Medical Corp.'s lead drug candidate?
Profound Medical Corp.'s most advanced tracked candidate is sonalleve (Approved) for Uterine fibroids, adenomyotic tissue, bone metastases pain, osteoid osteoma, and benign desmoid tumors.
Who is the CEO of Profound Medical Corp.?
Dr. Arun Swarup Menawat MBA, Ph.D. is the chief executive officer of Profound Medical Corp. (PROF).
Where is Profound Medical Corp. headquartered?
Profound Medical Corp. (PROF) is headquartered in Mississauga, ON, Canada.
What therapeutic areas does Profound Medical Corp. focus on?
Profound Medical Corp. develops therapies across Oncology, Pain, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.